Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01PZD
|
|||
| Former ID |
DCL000629
|
|||
| Drug Name |
Romiplostim
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Thrombocytopenia [ICD-11: 3B64] | Approved | [1], [2] | |
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90] | Phase 2 | [3], [4], [5] | ||
| Myelodysplastic syndrome [ICD-11: 2A37] | Phase 2 | [1], [6] | ||
| Company |
Amgen
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H14N2O
|
|||
| Canonical SMILES |
CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C
|
|||
| InChI |
1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-
|
|||
| InChIKey |
WUWDLXZGHZSWQZ-WQLSENKSSA-N
|
|||
| CAS Number |
CAS 194413-58-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
525180, 8034458, 10318718, 11061325, 12015099, 14847387, 17405666, 24278606, 26759729, 26759733, 39301723, 47207480, 47348964, 47572946, 49674962, 49984916, 50076383, 50107014, 50107015, 50107016, 53778216, 53789746, 56312333, 56312335, 56312337, 56312516, 56312518, 56312520, 56320689, 56322916, 57361292, 74446362, 85789116, 90341564, 91722386, 92303403, 99302833, 103175684, 113911626, 121362026, 121493282, 124750244, 124800944, 124891688, 134339165, 134339435, 134340578, 134341737, 135079569, 135141433
|
|||
| ChEBI ID |
CHEBI:91083
|
|||
| SuperDrug ATC ID |
B02BX04
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6974). | |||
| REF 2 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5056). | |||
| REF 4 | A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br J Cancer. 2005 Oct 17;93(8):876-83. | |||
| REF 5 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||
| REF 6 | Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. | |||
| REF 7 | SU5416, a VEGF Receptor Inhibitor and Ligand of the AHR, Represents a New Alternative for Immunomodulation | |||
| REF 8 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93. | |||
| REF 9 | Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9. | |||
| REF 10 | Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96. | |||
| REF 11 | New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven a... J Med Chem. 2000 Jun 15;43(12):2310-23. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.